News: AI Drug Development | NEC

Breadcrumb navigation

Press release

Nov 8, 2024: Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024NEW
Nov 7, 2024: NEC and NEC Bio publish foundational work on T Cell Receptor engineering using proprietary generative AI at the Society for Immunotherapy of Cancer annual meetingNEW
Oct 31, 2024: NEC Bio to Present Developments in the Oncology Field at the 39th Society of Immunotherapy for Cancer (SITC) Summit, 2024NEW
Aug 8, 2024: NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines
Jun 3, 2024: Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
Apr 10, 2024: Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Apr 8, 2024: NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
Mar 5, 2024: Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Jan 9, 2024: Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Sep 14, 2023: NEC selected by AMED for design of a universal vaccine that is effective against influenza virus strains

Sep 4, 2023: NEC OncoImmunity to Present Developments in the Infectious Diseases at 21st Awaji International Forum on Infection and Immunity, 2023
Aug 21, 2023: Nagasaki University and NEC OncoImmunity Collaborate to Design Universal Vaccines Targeting Tropical Infectious Diseases
Aug 8, 2023: Aichi Cancer Center and NEC Develop an Efficient Method for Identifying Lung Cancer Antigens and Antigen-Specific T Cells
Jul 27, 2023: NEC laboratories advances therapeutic cancer vaccine research with new AI model Attentive Variational Information Bottleneck
Jun 6, 2023: Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
Apr 18, 2023: New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
Mar 31, 2023: NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business
Mar 15, 2023: NEC and Transgene to present recent developments from TG4050 at the American Association of Cancer Research Conference
Jun 8, 2022: Updated Phase I Data with TG4050 Presented at ASCO 2022
Apr 18, 2022: Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
Apr 12, 2022: New Positive Preliminary Phase I Data on TG4050, an individualized therapeutic cancer vaccine jointly developed by NEC and Transgene, was presented at the AACR 2022
Apr 8, 2022: CEPI partners with Japan’s NEC Group to develop artificial intelligence-designed broadly protective betacoronavirus vaccine
Mar 8, 2022: NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets
Dec 15, 2021: BostonGene and NEC Announce Global Partnership
Nov 23, 2021: Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
Mar 8, 2021: NEC joins the CONNECT landmark public-private initiative for precision cancer medicine
Oct 8, 2020: NEC OncoImmunity AS and Oslo University Hospital team up to develop a diagnostic for COVID-19 using artificial intelligence
Oct 6, 2020: Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
Jul 21, 2020: BostonGene and NEC Collaborate to Analyze Cancer Patients in Clinical Trials
Jul 6, 2020: Aichi Cancer Center and NEC launch joint research on fundamental study aimed at advanced cancer immunotherapy through the fusion of AI and experimental immunology
May 25, 2020: NEC Laboratories Europe announces the start of pre-clinical validation studies for NEC’s AI-driven blueprint design for SARS-CoV-2 vaccine
May 15, 2020: Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
Apr 23, 2020: NEC publishes design blueprints for SARS-CoV-2 vaccines using its Artificial Intelligence technology
Mar 23, 2020: University of the Ryukyus and NEC discover a novel diagnostic biomarker for acute adult T-cell leukemia/lymphoma
- Discovery of elevated levels of soluble tumor necrosis factor receptor 2 -
Jan 7, 2020: Transgene and NEC Start Two Clinical Trials with TG4050,an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
Nov 12, 2019: NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
Jul 29, 2019: NEC acquires Norwegian bioinformatics company, OncoImmunity AS
May 27, 2019: NEC initiates AI-driven drug discovery business targeting a business valuation of ¥300 billion by 2025
May 14, 2019: NEC becomes the first Japanese company to join the TESLA consortium’s fight against cancer
Apr 26, 2019: Notice on Partial Amendment to the Articles of Incorporation
Apr 25, 2019: Biomedical Software Startup BostonGene Secures $50M in Series A Financing from NEC
Oct 30, 2018: NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy

In the News

Oct 24, 2024: [Health Awareness] How AI-powered cutting-edge technology is revolutionising vaccine developmentNEW
Apr 10, 2024: [AACR] Investigational Personalized Vaccine Provides Clinical Benefit for Some Patients with Resected Head and Neck Cancers
Jan 31, 2024: [NEC Stories]NEC's Promise in Preventing Infectious Disease: New Initiatives and the Power of One Team
Jan 14, 2023: [NHK WORLD-JAPAN]Tech firm crunches data for next-gen vaccine
Apr 11, 2022: [biopharma dealmakers] NEC: harnessing artificial intelligence-powered drug development to provide tailored medicines
Feb 26, 2021: [NEC Technical Journal] Development of Neoantigen — Targeted Cancer Vaccine Therapy
Jul 22, 2020: [Business Insights] NEC rises to the challenge of developing a COVID-19 vaccine
Jun 29, 2020: [Business Insights] NEC's AI-driven Blueprint for a Safe, Universally Effective New Coronavirus Vaccine
Jan 8, 2019: [Scrip] NEC Moves Beyond IT Tools As It Pursues AI-Driven Drug Discovery Initiative